Every letter we have printed

Access to a tissue is as important as the presence of a receptor in it, and molecules of this size do not cross every barrier freely. A receptor that cannot be reached is not part of the mechanism.

Gastric emptying delay is often treated as a side effect and it is at least partly a mechanism of the primary effect. That reframing changes how a reader should think about the management advice, and it is worth stating explicitly rather than leaving to be inferred.

I teach this material and the hardest habit to break is reasoning from mechanism to practice. A plausible pathway is a hypothesis, and a great deal of confident advice in this area is a hypothesis with the hedging removed. None of what I have written here is clinical advice and no reader should treat it as such.

I have been on treatment for fourteen months and stopped losing weight at month eleven. Your piece says this is energy balance rather than receptor desensitisation. I would find that easier to accept if anybody had explained it to me at the start rather than after I had spent two months assuming the drug had stopped working.

I keep back issues, which I do for no other publication I read, and the reason is that the reference material stays accurate for longer than the news does.

Your series has changed how I read a storefront and I would add one habit for other readers. Before looking at any mark, find the date. If there is no date anywhere on the page, the mark is decoration and the rest of the page should be read in that light.

A verified badge on a seller’s own page supports exactly one claim: that a document exists. It cannot support a claim about the lot in front of the buyer unless the badge resolves to a report identifying that lot, and almost none of them do.

The point your piece makes about documentation applies to custody with more force. A supplier that publishes its own handling record gives a buyer something to check; a supplier that publishes only a result gives them something to believe.

I would like to know how often a blind programme has been unable to complete a purchase — order cancelled, payment refused, nothing delivered. Those are results, they are never published, and they may be the most informative data any programme collects.

Intake relative to body mass changes during the study even when absolute intake is constant, and papers differ on which they report. The two produce different-looking results from identical data.

Where total intake falls sharply, meeting a protein target becomes a larger share of a smaller budget, and that is a practical problem rather than a theoretical one. The advice that ignores the constraint is the advice that does not get followed. None of this is dietary advice for any individual.

The precision of the instrument, the magnitude of the reported change and the duration of the study should always be given together. Any two of the three without the third leaves the reader unable to judge whether anything was measured at all.

As a DXA technologist of twenty-two years I would add one thing to your precision section: the largest source of error in practice is not the machine, it is positioning. A patient scanned with their arms two centimetres further from their trunk will report different regional values. We are trained to a protocol and the protocol is not always followed.

Thank you for declining to tell readers what to do. The restraint is unusual and it is the reason I trust what you do print.

Severity grading is doing a lot of quiet work. Most reported events sit in the mild to moderate categories, and a table that reports incidence without severity puts an inconvenience and a serious event in the same column.

The first-dose period accounts for a disproportionate share of reported events, and reporting a single study-wide incidence hides that structure entirely. A rate by week would be far more informative than a rate by trial.

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

Endoscopy has its own considerations distinct from general anaesthesia, and the two get merged in most coverage. Residual gastric contents affect the procedure itself and not only the airway question.

A point about the exposure profile rather than the receptor. Peak-to-trough variation differs substantially between compounds in this class, and a mechanism driven by peak exposure will present differently from one driven by average exposure. The literature rarely separates the two.

On archived certificates: ask for the previous three lots as well as the current one. A single document is a snapshot and tells you nothing about drift, and three consecutive ones will tell you more about the manufacturer than any individual figure on any of them.

Sample quantity is a provenance question in disguise. A determination performed on the whole vial and one performed on a few milligrams taken from the top of a settled cake are not equivalent, and neither the amount nor the sampling method appears on any certificate I have collected.

Age and baseline muscularity change the answer more than most sources admit. A finding averaged across a trial population is not a prediction about a person at either end of that distribution, and popular summaries convert averages into individual expectations almost automatically.

Age and sex distributions in the substudies differ substantially from the populations the figures are quoted about, and composition change is strongly patterned by both. Anybody reading a single ratio across a general population is discarding the two largest sources of structure in the data.

Divergence between practice and label is used as an argument in both directions and supports neither. That people do something differently is a fact about people, and it carries no information about whether it works.

Worth noting that the trial schedules were themselves designed for a trial, not for an individual. Fixed intervals suit an analysis plan and a supply chain. Clinicians departing from them are not necessarily departing from evidence; they are departing from a protocol that was built for a different purpose. Nothing in this letter is medical advice.

Case reports are hypothesis-generating and are cited as though they were confirmatory. A single well-documented case is genuinely valuable and it establishes that something can happen, not how often.

A publication covering this area sensibly cannot do more than describe how the literature classifies severe events and point the reader at proper clinical guidance. Your piece does that and resists the temptation to go further, which I think is the correct editorial position.

Muscle-derived enzymes appear in panels that are named for other organs, and any change in activity produces a change in them. It is the commonest benign explanation for a flagged result in an active population.

Transaminases falling as hepatic fat falls is one of the more consistent findings in this area, and it is worth stating that the direction is downwards, because readers primed to expect harm will read any liver panel with alarm.

A small thing but it matters in practice: your table gives amylase and lipase rising as a finding of unclear significance. In my laboratory we no longer report amylase at all for suspected pancreatitis, because lipase is more sensitive and more specific and having both invites the wrong one to be acted on.

The question I have learned to ask first is who commissioned the test. A certificate paid for by the seller, a certificate paid for by the buyer and a certificate paid for by a third party at the seller’s request are three different documents, and only one of them names the arrangement on its face.

Quantity tested against quantity released deserves a line. A determination on a hundred milligrams drawn from a five-kilogram campaign is a different kind of evidence from a determination on a vial drawn from a hundred-vial fill, and the certificate reports both in the same font.

The cloned-template problem is easy to detect and nobody does the detecting. Identical column identifiers, identical retention times to two decimals and different product names across four documents is not a coincidence, and it takes one careful reading to see. Buyers do not read certificates; they file them.

Dose-response data in this class flattens well before the top of the studied range on most endpoints, which is the actual argument against escalation. It is a stronger argument than the one usually made and it comes from published curves.

Body-size scaling is assumed in this discussion and was not built into the studied schedules, which are fixed rather than weight-based. Whether that is a finding or a convenience is not resolved anywhere in the literature.

I had a nine-week gap last year because my supplier stopped answering messages. Nobody in any clinical setting I dealt with treated that as a pharmacological event. Your framing of supply interruption as a dosing decision is the first time I have seen it written down.

A hold is a decision to accumulate more exposure at a given input, which is not the same as a decision to stop changing anything. The pharmacokinetics keep moving after the schedule stops.

A small thing. You give the semaglutide diabetes ladder as ending at 2.0 mg and the weight ladder at 2.4 mg, without explaining why the same molecule has two ceilings for two indications. It looks arbitrary and I suspect it is not.

Composition endpoints are collected in a minority of these studies and reported in fewer. A weight curve after withdrawal without a composition measurement leaves the most interesting question unanswered.

The analysis population in these designs is defined at randomisation, which is after the run-in has removed everybody who did not tolerate or did not respond. Every number downstream describes that filtered group and is quoted as though it described anybody.